April 29, 2004
Levitra awareness and interest expand erectile dysfunction (ED) market

Positive influence of Levitra on Bayer HealthCare's pharmaceuticals business

Global brand management prime example of focused strategy

- Sales of Levitra, Bayer's drug for the treatment of erectile dysfunction (ED) which was launched globally last year, reached €200 million at the end of the first quarter of 2004. Sales of Levitra in the first quarter of 2004 amounted to €66 million, double that of the fourth quarter of 2003 (€33 million).

The signs for future developments are likewise good. On April 23, 2004, Bayer HealthCare was granted approval for Levitra in Japan. Levitra had already received marketing authorization in Canada in March and is now approved in 83 countries. "The speed and breadth of Levitra launches throughout the world and the excellent global brand management are prime examples of Bayer Pharma's focus on driving growth of our key brands," said Dr. Wolfgang Plischke, Head of Bayer HealthCare's Pharmaceuticals Division.

The launch of Levitra in the United States, where the product has been available since August 2003, was one of the most successful new drug product launches in the past two years. Since its introduction to the market, Levitra has now been prescribed almost one million times in the United States alone.

Thanks to close-to-consumer marketing initiatives which have increased both awareness of and interest in Levitra, the brand has increasingly attracted international attention. These communication measures, which are tailored to meet men's needs while complying with the underlying regional legal conditions, have already led to a growing proportion of interested men consulting their physicians for information and requesting prescriptions for an effective drug product such as Levitra. Major PDE-5 markets have expanded between 20 to 50 percent since global introduction of Levitra and tadalafil, and in the U.S., physician visits for ED have increased by 78 percent.

"Our goal is to build the foundation for the future," said Plischke. "We have focused on growing and establishing Levitra in the market. We are confident that Levitra provides the fast-acting, reliable treatment that men are looking for in ED therapy, and acceptance of Levitra continues to increase worldwide. With the announcement of new clinical data, continued patient and physician education, and through innovative marketing initiatives we believe Levitra will achieve sustained success."

About Bayer HealthCare AG
Bayer HealthCare, a subgroup of Bayer AG with annual sales amounting to some €
8.9 billion in 2003, is one of the world's leading, innovative companies in the health care and medical products industry.

Bayer HealthCare combines the global activities of the Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals divisions. More than 34,600 employees work for Bayer HealthCare worldwide.

Our work at Bayer HealthCare is to discover and manufacture innovative products for the purpose of improving human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Forward-looking statements<br/>
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F).The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.